Business Context and Reporting Period
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company providing a minimally invasive treatment for severe emphyma, a form of chronic obstructive pulmonary disease (COPD). The company's solution includes the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX Platform. This filing covers the fiscal year ended December 31, 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $90.5 million | $83.8 million |
| Gross Margin | 74.2% | 74.0% |
| Net Loss | $(54.0) million | $(56.4) million |
| Operating Loss | $(53.7) million | $(57.7) million |
| Cash and Cash Equivalents (Year End) | $69.8 million | $70.9 million |
| Accumulated Deficit | $(521.6) million | $(467.6) million |
| Outstanding Debt (Year End) | $37.1 million | $37.1 million |
Note: Debt figures reflect the CIBC Loan outstanding as of December 31, 2025, prior to subsequent refinancing.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 8.0% ($6.7 million) year-over-year. Growth was driven primarily by international markets, which saw a $6.2 million increase, while U.S. sales grew modestly by $0.6 million.
- Operating Expenses: Total operating expenses increased slightly by 0.9%. Research and Development (R&D) expenses rose 10.9% due to increased clinical trial costs, while Selling, General, and Administrative (SG&A) expenses decreased 0.8% due to lower payroll and professional fees, partially offset by higher advertising spend.
- Interest Income: Interest income declined significantly by 47.6% to $2.7 million, attributed to lower balances of cash and marketable securities.
- Leadership Transition: In October 2025, the company announced the resignation of CEO Steven Williamson and CFO Mehul Joshi. Glendon E. French returned as President and CEO, and Derrick Sung rejoined as COO and CFO.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management expects to continue incurring net losses for the foreseeable future. As of December 31, 2025, the company had $69.8 million in cash. Management believes existing cash, combined with a new credit facility entered into on March 2, 2026, will fund operations for at least the next 12 months.
Subsequent Event (Debt Refinancing): On March 2, 2026, Pulmonx entered into a $60.0 million senior secured term loan facility with Perceptive Credit Holdings V, LP. The company borrowed an initial $40.0 million to repay its existing CIBC debt. The facility includes revenue-based tranches and warrants to purchase up to 1,000,000 shares.
Key Risks and Contingencies:
- Profitability: The company has a history of significant net losses and an accumulated deficit of $521.6 million. There is no assurance it will achieve or sustain profitability.
- Product Concentration: The business relies almost entirely on the Zephyr Valve. The AeriSeal System, designed to treat patients with collateral ventilation, is still in clinical trials (CONVERT II) and not yet approved for commercial sale in the U.S.
- Reimbursement: While major commercial payors have positive coverage policies, Medicare coverage is determined on a case-by-case basis without a National Coverage Determination (NCD). Changes in reimbursement policies could materially impact revenue.
- Legal Proceedings: A Qui Tam action under the False Claims Act was settled and dismissed in December 2025. The company is not currently a party to any material legal proceedings.
- Cybersecurity: The company relies on third-party providers for its LungTraX Platform. A security incident at a vendor (Intelerad) in January 2025 was investigated and determined not to have impacted Pulmonx's network, but supply chain risks remain.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Perceptive Credit Agreement covenants, specifically the minimum liquidity requirement of $4.0 million and revenue thresholds required to access additional tranches.
- Reimbursement Trends: Monitor the status of Medicare coverage determinations and any changes in commercial payor policies, as these directly impact hospital adoption.
- Clinical Trial Progress: Track the results and timeline of the CONVERT II pivotal trial for the AeriSeal System, which is critical for expanding the addressable market beyond patients without collateral ventilation.
- Leadership Stability: Assess the integration and performance of the new executive leadership team following the October 2025 transition.
- Inventory Levels: Review inventory valuation and long-term inventory classification ($3.6 million), as the company holds significant inventory to protect against supply interruptions.